The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis
Abstract
Objective: To study the quantitative and phenotypic reconstitution of peripheral blood B cells and its relationship to the dynamics of clinical response in patients with rheumatoid arthritis (RA) following B cell depletion with rituximab. Methods: Twenty‐four patients with active RA treated with rituximab were studied. Flow cytometry with combinations of monoclonal antibodies to B cell and T cell subsets was used. Results: The frequency and total number of CD19+ cells in the peripheral blood decreased a mean of 97% for more than 3 months in all but 1 patient following rituximab therapy. All B cell populations were depleted. More than 80% of residual B cells showed a memory or plasma cell precursor phenotype. B cell repopulation occurred a mean of 8 months after treatment and was dependent on the formation of naive B cells, which showed an increased expression of CD38 and CD5. During repopulation, increased numbers of circulating immature B cells, CD19+,IgD+,CD38 high ,CD10 low ,CD24 high cells, were identified. Patients who experienced a relapse of RA on return of B cells tended to show repopulation with higher numbers of memory B cells. A small number of T cells and natural killer cells expressed low levels of CD20. These cells were depleted following rituximab therapy and returned to the circulation a mean of 5 months after treatment. No other significant changes were detected in the T cell populations studied. Conclusion: Rituximab induced a profound depletion of all peripheral blood B cell populations in patients with RA. Repopulation occurred mainly with naive mature and immature B cells. Patients whose RA relapsed on return of B cells tended to show repopulation with higher numbers of memory B cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Self-citationDepletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Maloney, D., Liles, T., Czerwinski, D., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A., & Levy, R. (1994) · Blood · doi:10.1182/blood.v84.8.2457.2457 · Cited by 762
Identification and characterization of circulating human transitional B cells
Sims, G. P., Ettinger, R., Shirota, Y., Yarboro, C. H., Illei, G. G., & Lipsky, P. E. (2005) · Blood · doi:10.1182/blood-2004-11-4284 · Cited by 604
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
Edwards, J. C. W., & Cambridge, G. (2001) · Rheumatology · doi:10.1093/rheumatology/40.2.205 · Cited by 523
Self-citationPeripheral development of B cells in mouse and man
Carsetti, R., Rosado, M. M., & Wardmann, H. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.0109.x · Cited by 473
Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis
Cambridge, G., Leandro, M. J., Edwards, J. C. W., Ehrenstein, M. R., Salden, M., Bodman‐Smith, M., & Webster, A. D. B. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11181 · Cited by 470
Self-citationRituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus
Anolik, J. H., Barnard, J., Cappione, A., Pugh‐Bernard, A. E., Felgar, R. E., Looney, R. J., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20592 · Cited by 456
Sfikakis, P. P., Boletis, J., Lionaki, S., Vigklis, V., Fragiadaki, K., Iniotaki, A. G., & Moutsopoulos, H. Μ. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20858 · Cited by 410
Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion
Leandro, M. J., Edwards, J. C. W., & Cambridge, G. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.10.883 · Cited by 345
Self-citation
Cited by
von Büdingen, H.-C., Palanichamy, A., Lehmann-Horn, K., Michel, B. A., & Zamvil, S. S. (2015) · European Neurology · doi:10.1159/000377675 · Cited by 1,463
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Mackensen, A., Müller, F., Mougiakakos, D., Böltz, S., Wilhelm, A., Aigner, M., Völkl, S., Simon, D., Kleyer, A., Munoz, L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02017-5 · Cited by 1,092
New therapies for treatment of rheumatoid arthritis
Smolen, J. S., Aletaha, D., Koeller, M., Weisman, M. H., & Emery, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60784-3 · Cited by 995
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
B-cell targeting in rheumatoid arthritis and other autoimmune diseases
Edwards, J. C. W., & Cambridge, G. (2006) · Nature Reviews Immunology · doi:10.1038/nri1838 · Cited by 507
Self-citationUpdated consensus statement on the use of rituximab in patients with rheumatoid arthritis
Buch, M. H., Smolen, J. S., Betteridge, N., Breedveld, F. C., Burmester, G., Dörner, T., Ferraccioli, G., Gottenberg, J.-E., Isaacs, J., Kvien, T. K., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.144998 · Cited by 453
Menon, M., Blair, P. A., Isenberg, D. A., & Mauri, C. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.012 · Cited by 353
Anolik, J. H., Barnard, J., Owen, T., Zheng, B., Kemshetti, S., Looney, R. J., & Sanz, I. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22810 · Cited by 333
B‐lymphocyte contributions to human autoimmune disease
Yanaba, K., Bouaziz, J., Matsushita, T., Magro, C. M., St.Clair, E. W., & Tedder, T. F. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00646.x · Cited by 326
A review of the current use of rituximab in autoimmune diseases
Gürcan, H. M., Keskin, D. B., Stern, J. N. H., Nitzberg, M. A., Shekhani, H., & Ahmed, A. R. (2009) · International Immunopharmacology · doi:10.1016/j.intimp.2008.10.004 · Cited by 314
Therapeutic B cell depletion impairs adaptive and autoreactive CD4 + T cell activation in mice
Bouaziz, J.-D., Yanaba, K., Venturi, G. M., Wang, Y., Tisch, R. M., Poe, J. C., & Tedder, T. F. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709205105 · Cited by 314
Rituximab Therapy in Idiopathic Membranous Nephropathy: A 2-Year Study
Fervenza, F. C., Abraham, R. S., Erickson, S. B., Irazabal, M. V., Eirin, A., Specks, U., Nachman, P. H., Bergstralh, E. J., Leung, N., Cosio, F. G., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05080610 · Cited by 299
Kim, S.-H. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.154 · Cited by 295
Blair, P. A., Chavez-Rueda, K. A., Evans, J. G., Shlomchik, M. J., Eddaoudi, A., Isenberg, D. A., Ehrenstein, M. R., & Mauri, C. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803052 · Cited by 291
Self-citationRituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients
Palanichamy, A., Jahn, S., Nickles, D., Derstine, M., Abounasr, A., Hauser, S. L., Baranzini, S. E., Leppert, D., & von Büdingen, H.-C. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400118 · Cited by 289
Role of B Cells in Multiple Sclerosis and Related Disorders
Comi, G., Bar‐Or, A., Lassmann, H., Uccelli, A., Hartung, H., Montalban, X., Sørensen, P. S., Hohlfeld, R., Hauser, S. L., & Expert Panel of the 27th Annual Meeting of the European Charcot Foundation (2021) · Annals of Neurology · doi:10.1002/ana.25927 · Cited by 283
B cells move to centre stage: novel opportunities for autoimmune disease treatment
Browning, J. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2085 · Cited by 279
Advances in Human B Cell Phenotypic Profiling
Kaminski, D. A., Wei, C., Qian, Y., Rosenberg, A. F., & Sanz, I. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00302 · Cited by 272
Rituximab in severe, treatment-refractory interstitial lung disease
Keir, G. J., Maher, T. M., Ming, D., Abdullah, R., de Lauretis, A., Wickremasinghe, M., Nicholson, A. G., Hansell, D. M., Wells, A. U., & Renzoni, E. A. (2014) · Respirology · doi:10.1111/resp.12214 · Cited by 256
Smith, R. M., Jones, R. B., Guerry, M., Laurino, S., Catapano, F., Chaudhry, A., Smith, K. G. C., & Jayne, D. R. W. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34583 · Cited by 250
Age-associated B cells in autoimmune diseases
Mouat, I. C., Goldberg, E., & Horwitz, M. S. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04433-9 · Cited by 170
B Cells in Rheumatoid Arthritis: From Pathogenic Players to Disease Biomarkers
Bugatti, S., Vitolo, B., Caporali, R., Montecucco, C., & Manzo, A. (2014) · BioMed Research International · doi:10.1155/2014/681678 · Cited by 170
Doyle, T. J., Dhillon, N., Madan, R., Cabral, F., Fletcher, E. A., Koontz, D. C., Aggarwal, R., Osorio, J. C., Rosas, I. O., Oddis, C. V., et al. (2018) · The Journal of Rheumatology · doi:10.3899/jrheum.170541 · Cited by 102
Mensah, F., Bansal, A., Berkovitz, S., Sharma, A., Reddy, V, Leandro, M. J., & Cambridge, G. (2016) · Clinical and Experimental Immunology · doi:10.1111/cei.12749 · Cited by 34
Self-citationLunde, S., Kristoffersen, E. K., Sapkota, D., Risa, K., Dahl, O., Bruland, O., Mella, O., & Fluge, Ø. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161226 · Cited by 22
Metadata
- Authors
- Leandro, M. J., Cambridge, G., Ehrenstein, M. R., & Edwards, J. C. W.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2006-01-30
- Volume
- 54
- Issue
- 2
- Pages
- 613-620
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1998618256
- Cited by
- 560
- References
- 22
- FWCI
- 27.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.